Thus, during the clinical course of imiquimod-induced psoriasis-like skin inflammation, the amplification of Th17 responses caused by the up-regulation of IL-23 expression, the impairment in type I interferon and inflammatory cytokines and the decrease in IL-10 expression occurred in IRF5 KO mice. This evidence concerns the gene IL23A and dermatitis.